Cite
Xhakaza L, Abrahams-October Z, Pearce B, et al. Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients. Drug Metab Pers Ther. 2020;doi: 10.1515/dmdi-2020-0111.
Xhakaza, L., Abrahams-October, Z., Pearce, B., Masilela, C. M., Adeniyi, O. V., Johnson, R., Ongole, J. J., & Benjeddou, M. (2020). Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients. Drug metabolism and personalized therapy, . https://doi.org/10.1515/dmdi-2020-0111
Xhakaza, Lettilia, et al. "Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients." Drug metabolism and personalized therapy vol. (2020). doi: https://doi.org/10.1515/dmdi-2020-0111
Xhakaza L, Abrahams-October Z, Pearce B, Masilela CM, Adeniyi OV, Johnson R, Ongole JJ, Benjeddou M. Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients. Drug Metab Pers Ther. 2020 Jun 30; doi: 10.1515/dmdi-2020-0111. Epub 2020 Jun 30. PMID: 32609649.
Copy
Download .nbib